ASCEND-4: Upfront Ceritinib in ALK-Rearranged NSCLC

Tony Mok, MD; David Spigel, MD; and Alice Shaw, MD, PhD, describe the study design and results of the phase III ASCEND-4 trial looking at upfront ceritinib versus chemotherapy in ALK-rearranged non–small cell lung cancer.